Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 1Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

fludarabine 63Cyclophosphamide 63venetoclax 57Azacitidine 52fludarabine phosphate 50Specimen Handling 44Whole-Body Irradiation 40ruxolitinib 37Mycophenolic Acid 37Tacrolimus 35Melphalan 32Busulfan 32Biopsy 32Cytarabine 31Stem Cell Transplantation 27Decitabine 27Granulocyte Colony-Stimulating Factor 21asciminib 19decitabine and cedazuridine drug combination 18Sirolimus 18Peripheral Blood Stem Cell Transplantation 18Injections 18Thiotepa 17Filgrastim 17nilotinib 15X-Rays 14Methotrexate 14Cyclosporine 14Imatinib Mesylate 13Magnetic Resonance Spectroscopy 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
JNJ-64264681 × Myeloid × 1 year × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡